NEW YORK (GenomeWeb News) – Bayer today said that its Bayer HealthCare business has joined the non-profit Structural Genomics Consortium.

Bayer will provide funding to the consortium to accelerate drug research in the areas of protein science and epigenetics. In addition, it will collaborate with the consortium on research projects to identify small molecules that can interfere with protein activity involved in epigenetic control. Bayer also said that ti will provide a subset of its compound library to the SGC for screening.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.